Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5275852
Max Phase: Preclinical
Molecular Formula: C17H11BrCl2N2O
Molecular Weight: 410.10
Associated Items:
ID: ALA5275852
Max Phase: Preclinical
Molecular Formula: C17H11BrCl2N2O
Molecular Weight: 410.10
Associated Items:
Canonical SMILES: Cc1nc2ccc(Br)cc2c(=O)n1/C=C/c1c(Cl)cccc1Cl
Standard InChI: InChI=1S/C17H11BrCl2N2O/c1-10-21-16-6-5-11(18)9-13(16)17(23)22(10)8-7-12-14(19)3-2-4-15(12)20/h2-9H,1H3/b8-7+
Standard InChI Key: QRODGZXSTOGGBJ-BQYQJAHWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 410.10 | Molecular Weight (Monoisotopic): 407.9432 | AlogP: 5.40 | #Rotatable Bonds: 2 |
Polar Surface Area: 34.89 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 4.61 | CX LogP: 5.08 | CX LogD: 5.08 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.57 | Np Likeness Score: -1.00 |
1. Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B.. (2018) An overview of quinazolines: Pharmacological significance and recent developments., 151 [PMID:29656203] [10.1016/j.ejmech.2018.03.076] |
Source(1):